Table 2 Specific factors to consider for intravitreal brolucizumab treatment.

From: The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice

Cautionary criteria for brolucizumab based on clinical experts’ opinion

• History of any intraocular inflammation (IOI).

• Patients with prior history of retinal vasculitis.

• Eyes with scleritis and episcleritis may be excluded at the discretion of the treating physician.

• Previous culture-negative endophthalmitis.

• The evidence on efficacy and adverse events of brolucizumab is continually evolving; there is a need to review the data and seek advice as necessary from lead or senior consultants.

Back to article page